Bo Lennernäs

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study

Sten Nilsson, Lars Franzén, Christopher Parker et al. · The Lancet Oncology · 2007 · 493 citations

Medicine, Oncology, Radiation Oncology +15

In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance

Susanne Bredenberg, M. Duberg, Bo Lennernäs et al. · European Journal of Pharmaceutical Sciences · 2003 · 121 citations

Pharmacy, Pharmaceutics, Pharmacology +17

Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases

Sten Nilsson, Lars Franzén, Christopher Parker et al. · Clinical Genitourinary Cancer · 2012 · 119 citations

Medicine, Oncology, Radiation Oncology +17

Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain

Bo Lennernäs, Thomas Hedner, M. B. Holmberg et al. · British Journal of Clinical Pharmacology · 2005 · 96 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin

Jan‐Erik Damber, Christina Vallbo, Per Albertsson et al. · Cancer Chemotherapy and Pharmacology · 2005 · 89 citations

Medicine, Oncology, Pharmacology +6